[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.239.150.57. Please contact the publisher to request reinstatement.
Viewpoint
February 2015

Dermatologists, Imiquimod, and Treatment of Molluscum Contagiosum in Children: Righting Wrongs

Author Affiliations
  • 1Department of Dermatology, Kaiser Permanente, Pleasanton, California
JAMA Dermatol. 2015;151(2):125-126. doi:10.1001/jamadermatol.2014.3335

“Half of what we’re teaching you is wrong,” one of my medical school deans would often say. “The problem,” he would continue, “is that we don’t know which half.”

The dean was wise. Consider the case of imiquimod, long widely considered beneficial for treatment of molluscum contagiosum. It actually is not, as 2 large randomized clinical trials (RCTs) showed.1,2 The catch is that those 2 RCTs were never published. As a result, physicians—including, especially, dermatologists—continue to prescribe the drug for molluscum contagiosum in children. It’s time we stopped doing that.

×